IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Graham Nigel Maw, et al. :

APPLICATION NO.: Not Yet Assigned : Examiner:

FILING DATE: Herewith : Group Art Unit:

TITLE: Compounds for the Treatment of Female Sexual:

Dysfunction

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s). The references for this application can be found in the parent case U.S. Non-Provisional Application No. 09/708,392.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Arlene K. Musser

Attorney for Applicant(s)

Reg. No. 37,895

Pfizer Inc.

Patent Department, MS 8260-1611

Date: October 15, 200 3

Eastern Point Road

Groton, Connecticut 06340

(860) 715-0871

EXPRESS MAIL NO. EV 398059916 US-

INFORMATION DISCLOSURE CITATION					A.	ATTY. DOCKET NO. PC10343C SERIAL NO.Not Yet Assigned					ned					
(Use several sheets if necessary)						APPLICANT Graham Nigel Maw, et al.										
(555 5575.2. 5.15515 // 11055552.3)						FILING DATE Herewith GROUP										
	U.S. PATENT DOCUMENTS															
EXAMINE	₹	<u> </u>			DOC	UMENT NUM				DATE	NAME	CL	ASS	SUBCLASS	FILING	3 DATE
INITIAL 7S.K.7	+	+		-		· · · · · · · · · · · · · · · · · · ·										OFMATE
7S.K./	US	3	4	6	6	6	9	0	8	5/19/87	Hamilton	5	14	229		
	US	3	5	5	7	4	0	6	8	11/12/96	Stamler, et a	al. 5	14	562	<u></u>	
7\$.K.7	Us	3	5	9	8	1	5	2	7	11/9/99	Daugan, et a	al. 5	14	290		
/S.K./	U	T	5	۰	6		3	9	6	1/19/99	Niewebner e	t al 5	14	234.2		
78.K./	100	+	3 _	8	В	1		1 9		1/19/99	Niewohner, e	tai. 5	14	234.2		
78.K./	US	-	5	6	1	2	3	1	4	3/18/97	Stamler, et a	al. 5	14	13		
	US	3	6	0	4	3	2	5	2	3/28/00	Bombrun	5	14	292	<u> </u>	
/S.K./	US	<u>. </u>	6	2	9	4	5	5	0	9/25/01	Place, et a	l. 5	14	302		
/S.K./	Us		6	3	1	6	4	5	7	11/13/01	Garvey, et a	n 5	14	263		
/S.K./	US						8				•					
	1.08	<u> </u>	6	3	0 [6		IGN PAT	ENT DO	10/23/01 OCUMEN	Place, et al	l. 3	14	149		
										1						
				DO	CUMENT NU	MBER				DATE	COUNTRY	CL	ASS	SUBCLASS	TRANS	SLATION
/S.K./	1				Ι	1		1	l					l I	YES	NO
	EF	>	0	9	11	1 1	3	3	3	4/24/99	European	CC)7D	487/04		
/S.K./	EF	,	0	7	7	1	7	9	9	7/5/97	European	co)7D	473/00		
/S.K./	E		0	2	7	4	4	3	4	7/13/88	European	CO)7D	409/06		
/S.K./																
/S.K./	/ W	7	9	1	0	4	0	4	2	4/4/91	Internationa	al A6	51K	37/02		
10 K /	W		9	7	2	0	8	2	1	6/12/97	Internationa	al CO)7D	239/95		
/S.K./	w	<u> </u>	9	7	3	5	9	8	9	10/2/97	Internationa	al C1	I2N	15/55		
/S.K./	w		9	7	3	9	7	6	0	10/30/97	Internationa	al A6	51K	33/26		
/S.K./	w		9	8	0	3	4	9	2	1/29/98	Internationa) C)7D	295/18		
/S.K./										·						
75.K./	_ w	-	9	9	2	0	2	6	6	4/29/99	Internationa	al A6	61K	31/19		-
/S.K./	w	<u> </u>	9	9	2	1	5	6	2	5/6/99	Internationa	al A6	61K_	31/557		
	w		9	9	2	2	7	3	1	5/14/99	Internationa	al A6	31K	31/44		
/S.K./	W	,	0	0	1	5	6	3	9	3/23/00	Internationa	<u>ıl</u> C0)7D_	471/04		
/S.K./	w	_ ا	0	0	1	5	2	2	8	3/23/00	Internationa		51K	31/4985		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																
/S.K.																

INFORM	MATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10343C	SERIAL NO.Not Yet Assigned					
(Us	e several sheets if necessary)	APPLICANT Graham Nigel Maw, et al.						
		FILING DATE Herewith	GROUP					
/S.K./	Palle, Bredkjaer, Ottesen and Fahrer	krug 1990 Clinical and Experimental Pharmacolo	ogy and Physiology vol 17, 61-68.					
/S.K./	Beavo JA and Reifsnyder DH, Trend	s Pharmacol. Sci. 11:150 (1990).						
7S.K./	Wieshaar RE et al., J. Med. Chem., 2	Wieshaar RE et al., J. Med. Chem., 28, 537 (1985).						
/S.K./		Giembycz MA, <i>Biochem. Pharm.</i> , 43 :2041 (1992).						
7S.K.								
/S.K./	Ashur-Fabian, O., Perl, O., Lilling, C	Lowe JA and Cheng JB, <i>Drugs for the Future</i> , 17 , 799-807 (1992). Ashur-Fabian, O., Perl, O., Lilling, G., <i>et al.</i> ,. "SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival," <i>Peptides</i> , 20 , 629-633 (1999).						
/S.K./		Berman, J.R., Berman, L. & Goldstein, I., "Female sexual dysfunction: Incidence, pathophysiology, evaluation, and treatment options," <i>Urology</i> , 54 , 385-391 (1999).						
/S.K./		Berman, J., Goldstein, I., Werbin, T. et al., "Double blind placebo controlled study with crossover to assess effect of slidenafil on physiological parameters of the female sexual response," J. Urol., 161, 805 (1999)						
/S.K./	Burnett, A, Calvin, D., Silver, R. et al. 158, 75-78 (1997).	Burnett, A, Calvin, D., Silver, R. et al. "Immunohistochemical description of nitric oxide synthase isoforms in human clitoris," J. Urol., 158, 75-78 (1997).						
/S.K./	Diagnostic and statistical manual of r	Diagnostic and statistical manual of mental disorders-IV, American Psychiatric Association: Washington, DC., pp. 493-518 (1987).						
7S.K./		Fan, Y.P., Chakder, S & Ratton, S., "Inhibitory effect of zinc protoporphyrin IX on lower esophageal sphincter smooth muscle relaxation by vasoactive intestinal polypeptide and other receptor agonists," <i>J. Pharmacol. Exp. Ther.</i> , 285 , 468-474 (1998).						
/S.K./	Foda, H.D., Sharaf, H.H. Absood, prolonged airway smooth muscle rela	Foda, H.D., Sharaf, H.H. Absood, A. et al., "Pituitary adenylate cyclase-activating peptide (PACAP), a VIP-like peptide, has prolonged airway smooth muscle relaxant activity," <i>Peptides</i> , 16 , 1057-1061 (1995).						
/S.K./	Frank, E., Anderson, C. & Rubinste (1978).	in, D. "Frequency of sexual dysfunction in "norr	mal" couples," N. Engl. J. Med., 229, 111-115					
/S.K./	Goldstein, I. & Berman, J.R. "Vaso syndromes," Int. J. Impot. Res., 10, S	Goldstein, I. & Berman, J.R. "Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes," <i>Int. J. Impot. Res.</i> , 10 , S84-S90 (1998).						
/S.K./	Gu, Z.F., Jensen, R.T. & Maton, P. agonists and neuropeptides,". Am J.	Gu, Z.F., Jensen, R.T. & Maton, P.N. "A primary role for protein kinase A in smooth muscle relaxation induced by adrenergic agonists and neuropeptides,". Am J. Physiol., 263, G360-G364 (1992).						
/S.K./	Hauser-Kronberger, C., Cheung, A.,	Hauser-Kronberger, C., Cheung, A., Hacker, G. et al., "Peptidergic innervation of the human clitoris," Peptides, 20, 539-543 (1999).						
/S.K./	Hoyle, C.H.V., Stones, R.W., Robson neuropeptide containing nerves," J. A	Hoyle, C.H.V., Stones, R.W., Robson, T. et al., "Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide containing nerves," J. Anat., 188, 633-644 (1996).						
/S.K./	Ingenhoven, N. & Beck-Sickinger, expressing NPY receptor subtypes,"	Ingenhoven, N. & Beck-Sickinger, A.G. "Flourescent labelled analogues of neuropeptide Y for the characterisation of cells expressing NPY receptor subtypes," <i>J. Recept. Signal Transduct. Res.</i> , 17, 407-418 (1997).						
/S.K./	Jovanovic, A., Jovanovic, S., Tulic, polypeptide in human uterine artery,"	Jovanovic, A., Jovanovic, S., Tulic, I. et al., "Predominant role for nitric oxide in the relaxation induced by vasoactive intestinal polypeptide in human uterine artery," Mol. Human Reprod., 4, 71-76 (1998).						
/S.K./	Kaplan, S.A., Reis, R.B., Kohm, I.J. Urology, 53 , 481-486 (1999).	Kaplan, S.A., Reis, R.B., Kohm, I.J. et al., "Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction," <i>Urology</i> , 53 , 481-486 (1999).						
/S.K./		Kim, Y.C., Choi, H.K., Ahn, Y.S., et al. "The effect of vasoactive intestinal polypeptide (VIP) on rabbit cavernosal smooth muscle contractility," J. Androl., 15, 392-397 (1994).						
/S.K./	Laan, E. & Everaerd, W. "Physiologic	Laan, E. & Everaerd, W. "Physiological measures of vaginal vasocongestion,". Int. J. Impot. Res., 10, S107-S110 (1998).						
7S.K.	Leiblum, S.R. "Definition and classific	ation of female sexual disorders," Int. J. Impotent	ce Res., 10, S104-S106 (1998).					

INFORM	ATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10343C	SERIAL NO.Not Yet Assigned				
(Use	e several sheets if necessary)	APPLICANT Graham Nigel Maw, et al.					
		FILING DATE Herewith	GROUP				
7S.K/	Levin, R.J., "The physiology of sexua	I function in women," Clin. Obstet. Gynecol., 7, 2	213-252 (1980).				
/S.K./	Levin, R.J., "VIP, vagina, clitoral and preurethral glans.: An update on female genital arousal," Exp. Clin. Endocrinol., 98, 61-69 (1991).						
75.K/	Levin, R.J., "The mechanisms of human female sexual arousal," Ann. Rev. Sex Res., 3, 1-48 (1992).						
/s.k./	Levin, R.J., & Wagner, G.) "TRH and vaginal blood flow-effects in conscious women and anaesthetized sheep," J. Physiol., 378, 83P (1986)						
/S.K./	Lundberg, J.M., Modin, A. & Malmstrom, R.E. "Recent developments with neuropeptide Y receptor antagonists," <i>Trends. Pharmacol. Sci.</i> , 17 , 301-304 (1996).						
/S.K./	Ottesen, B., Gerstenberg, T. Ulrichsen, H. et al., "Vasoactive intestinal oplypeptide (VIP) increases vaginal blood flow and inhibits smooth muscle activity in women," Eur. J. Clin. Invest., 13, 321-324 (1983).						
/S.K./	Ottesen, B., Wagner, G & Fahrenkrug, J., <i>Peptide innervation of the sexual organs</i> . In: Handbook of Sexology, Vol. 6, The Pharmacological and Endocrinology of Sexual Function, Sitsen, J.M.A. (eds), Amsterdam: Elsevier Science Publishers, chapter 4, pp 66-97. (1988).						
/S.K./	Ottensen, B. Pedersen, B., Nielsen, 8, 797-800 (1987).	Ottensen, B. Pedersen, B., Nielsen, J. et al., "Vasoactive polypeptide (VIP) provokes vaginal lubrication in normal women," <i>Peptides</i> , 8 , 797-800 (1987).					
/S.K/	Park, K., Goldstein, I., Andry, C., et al.,. "Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency," Int. J. Impotence Res., 9, 27-37 (1997).						
75.K./	Rosen, R. Taylor, J., Leiblum, S. et al., "Prevalence of sexual dysfunction in women: results of a survey of 329 women in an outpatient gynecological clinic," J. Sex Marital Ther., 19, 171-188 (1993).						
7S.K./	Schiavi, R.C. & Seagraves, R.T., "The biology of sexual function," Psychiat. Clin. North. Am., 18, 7-23 (1995).						
/S.K./	Schoeffter, P. & Stoclet, J.C., "Effect of vasoactive intestinal polypeptide (VIP) on cyclic AMP level and relaxation in rat isolated aorta," Eur. J. Pharmacol., 109, 275-279 (1985).						
/S.K./	Serradeil-Le Gal, C., Valette, G., Rouby, P.E. et al., "SR 120819A, an orally-active and selective neuropeptide Y Y1 recptor antagonist," FEBS Letters, 3, 192-196 (1995).						
/S.K./	Sjoberg, I. "The vagina: Morphological, functional and ecological aspects," Acta Obst. Gynecol. Scand., 71, 84-85 (1992).						
/S.K./	Spector, I.P. & Carey, M.P. "Incidence and prevalence of sexual dysfunctions: a critical review of the empirical literature," <i>Arch. Sex. Behav.</i> , 19 , 389-408 (1990).						
/S.K./	Wagner, G. "Aspects of genital physiology and pathology," Sem. Neurol., 12, 87-97 (1992).						
/S.K./	Werbin, T., Salimpour, P., Berman, L., et al., "Effect of sexual stimulation and age on genital blood flow in women and sexual stimulation," J. Urol., 161, 688 (1999).						
/S.K./	Wincze, J.P., Albert, a. & Bansal, S. "Sexual arousal in diabetic females: Physiological and self-report measures," <i>Arch. Sex Behav.</i> , 22 , 587-601 (1993).						
/S.K./	Wieland, H.A., Willim, K.D., Entzeroth, M. et al., "Subtype selectivity and antagonist profile of the nonpeptide Y1 receptor antagonist BIBP 3226," J Pharmacol Exp Ther., 275, 143-9 (1995).						
/S.K./		Ottesen, B. American Journal of Obstetrics & Gynecology, "Vasoactive Intestinal Peptide as a Neurotransmitter in the Female Genital Tract", Volume 147, pages 208-224 (1983)					
/S.K./	Clark, J.T., et al., <u>Endocrinology</u> , "Ne pages 2435-2442 (1985)	Clark, J.T., et al., Endocrinology, "Neuropeptide Y Stimulates Feeing But Inhibits Sexual Behavior in Rats", Volume 117, No. 6.,					
/S.K./	Suzuki, H., et al., <u>American Journal c</u> Cheek Pouch Vessels in Situ", Volun	Suzuki, H., et al., American Journal of Physiology, "Neutral Endopeptridase Modulates VIP-induced Vasodilalation In Hamster Cheek Pouch Vessels in Situ", Volume 271, No. 2, Part. 2, pages R393-R397 (1996)					
/S.K./	Erdos, E.G., et al., <u>Laboratory Invest</u> 737-747 (1985)	igation, "Neutral Metalloendopeptidase In Humar	n Male Genital Tract", Volume 52, No. 4, pages				

INFORMAT	TION DISCLOSURE CITATION	ATTY, DOCKET NO. PC10343C	SERIAL NO.Not Yet Assigned				
,,,,,,							
(Use s	everal sheets if necessary)	APPLICANT Graham Nigel Maw, et al.					
		FILING DATE Herewith	GROUP				
/s.k./	United States Non-Provisional Patent Treatment of Female Sexual Dysfund	t Application No. 09/708,344, filed November attom", (Our Docket No. PC10931A)	8, 2000; Maw, et al., "Compounds for the				
/S.K./	United States Non-Provisional Patent Application No. 09/708,365, filed November 8, 2000; Maw, et al., "Compounds for the Treatment of Female Sexual Dysfunction", (Our Docket No. PC10932A)						
/S.K./	United States Non-Provisional Patent Application No. 09/708,393, filed November 8, 2000; Maw, et al., "Compounds for the Treatment of Female Sexual Dysfunction", (Our Docket No. PC10930A)						
/S.K./	Hedlund, et al., <u>PNASu</u> , "Erectile Dysfunction in Cyclin GMP-Dependent Kinase I-Deficient Mice", Volume 97, No. 5, pages 2349-2354 (2000)						
/S.K./	U.S. 2002-0052370, filed April 02; Ba	rber, et al., 514/237.5					
/S.K./	U.S. 2002-0169101, filed November 2002; Gonzalez, et al., 514/1						
/S.K./	US 2002/0028846						
/S.K./	US2001/0051656						
/S.K./	US2002/0019405						
EXAMINER	/Shobha Kantamneni/	DATE CONSIDERED	09/12/2008				

Conforms with FORM PTO-FB-A820